Mock NK-92 (25.7 ± 3.3% CD107a+) and CD19-CAR NK-92 (24.9 ± 3.9% CD107a+) displayed equal levels of CD107a expression in response to CD19− BCMA+ U266, indicating that CAR transfection does not impact their natural tumor reactivity. This evidence concerns the gene LAMP1 and neoplasm.